|
|
Doug Ross is a C-suite executive with extensive experience translating scientific breakthroughs into marketed products that are at the center of building value for diagnostic and life science platform companies. His executive roles have included founding a diagnostic start-up company that was acquired by Clarient Inc, a national pathology reference lab subsequently acquired by GE Healthcare. As consulting CSO to Life Technologies, he played a central role in an M&A transactions and integration that created an in vitro diagnostic test that helped pioneer NGS variant testing in cancer. Most recently, he has served on the executive leadership team at Oncocyte Inc, leading R&D and Medical Affairs through a turn-around phase, acquisition of three early-stage start-ups, and validation and launch of three proprietary products. He is known for his integrity, credibility, and insight at the intersection of science, medicine, product development and creating value for shareholders.
Doug holds an MD and PhD from the University of Washington and Fred Hutchinson Cancer Research Center, did Laboratory Medicine training at U. California at San Francisco, post-doctoral training at Stanford University, and has published over 40 peer-reviewed publications including lead authorship in articles published in Nature Genetics, Journal of Clinical Oncology and Clinical Cancer Research.
Doug holds an MD and PhD from the University of Washington and Fred Hutchinson Cancer Research Center, did Laboratory Medicine training at U. California at San Francisco, post-doctoral training at Stanford University, and has published over 40 peer-reviewed publications including lead authorship in articles published in Nature Genetics, Journal of Clinical Oncology and Clinical Cancer Research.
